HSV-1 and HSV-2 vaccines and methods of use thereof
This invention provides methods of treating, suppressing, inhibiting, reducing an incidence, reducing the pathogenesis of, ameliorating the symptoms of, or ameliorating the secondary symptoms of a primary or recurring Herpes Simplex Virus (HSV) infection, or prolonging the latency to a relapse of an HSV infection, and disorders and symptoms associated with same and inducing an anti-HSV immune response in a subject comprising the step of contacting the subject with a composition comprising a mutant HSV strain comprising an inactivating mutation in a Us8 gene, followed by a second contacting with the composition.
1. A method of suppressing a recurrent Herpes Simplex Virus (HSV) infection in a subject comprising the steps of:
a) administering a composition comprising a mutant HSV-2 strain to said subject, wherein said mutant HSV-2 strain consists of a single inactivating mutation, wherein said inactivating mutation consists of the deletion of base pairs (bp) 369-1479 of SEQ ID NO: 7, and
b) following step a) a second administration of said composition comprising said mutant HSV-2 strain is performed.
2. The method of claim 1 , wherein said composition is first administered before exposure to HSV.
3. The method of claim 1 , wherein said composition is first administered after exposure to HSV.
4. The method of claim 1 , wherein said mutant strain has a defect in anterograde neuronal transport, retrograde spread, and is deficient in cell-to-cell spread.
5. The method of claim 1 , wherein said mutant strain is replication-competent.
6. The method of claim 1 , wherein said mutant HSV strain induces an anti-HSV immune response in said subject.
7. The method of claim 6 , wherein said anti-HSV immune response is an anti-HSV neutralizing antibody response.
8. The method of claim 1 , wherein said HSV infection is an HSV-1 infection.
9. The method of claim 1 , wherein said HSV infection is an HSV-2 infection.
10. The method of claim 1 , wherein said HSV infection is a genital infection.
11. The method of claim 1 , wherein said HSV infection is an oral infection.
12. The method of claim 1 , wherein said HSV infection is an ocular HSV infection.
13. The method of claim 1 , wherein said recurrent HSV infection is HSV labialis following a primary HSV infection.
14. The method of claim 1 , wherein said composition is administered at least one additional time after said second administration.
15. The method of claim 1 , wherein said composition is administered intramuscularly, epidermally, subcutaneously, intravaginally, or via intra-respiratory mucosal injection.